RNXT
RNXT
NASDAQ · Biotechnology

Renovorx Inc

$1.57
+0.02 (+1.29%)
As of Sep 29, 10:18 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.41M
Net Income
-14,015,166
Gross Margin
70.9%
Profit Margin
-994.5%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 70.9% 48.8% 48.8% 48.8%
Operating Margin -1,114.0% 26.8% 30.6% 31.5%
Profit Margin -994.5% 20.7% 24.4% 20.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.41M 3.79M 3.81M 2.96M
Gross Profit 999.4K 1.85M 1.86M 1.45M
Operating Income -15,706,449 1.02M 1.16M 933.6K
Net Income -14,015,166 783.4K 928.9K 608.3K
Gross Margin 70.9% 48.8% 48.8% 48.8%
Operating Margin -1,114.0% 26.8% 30.6% 31.5%
Profit Margin -994.5% 20.7% 24.4% 20.5%
Rev Growth — +6.9% +13.5% +17.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 13.03M 11.58M 13.18M
Total Equity — 14.21M 15.57M 13.44M
D/E Ratio — 0.92 0.74 0.98
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -15,695,567 1.80M 1.92M 1.50M
Free Cash Flow — 820.9K 949.0K 713.4K